Intellia Therapeutics Inc. is a Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9.
Intellia Therapeutics Inc. (NTLA) had a good day on the market for Friday December 04 as shares jumped 1.21% to close at $43.44. About 1.55 million shares traded hands on 17,251 trades for the day, compared with an average daily volume of n/a shares out of a total float of 59.08 million. After opening the trading day at $43.00, shares of Intellia Therapeutics Inc. stayed within a range of $44.00 to $40.10.
With today’s gains, Intellia Therapeutics Inc. now has a market cap of $2.57 billion. Shares of Intellia Therapeutics Inc. have been trading within a range of $43.73 and $9.19 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema and ex vivo programs targeting Wilms Tumor 1 for acute myeloid leukemia.
Intellia Therapeutics Inc. is based out of Cambridge, MA and has some 270 employees. Its CEO is John M. Leonard.